12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Company News  |  Deals

Liquidia, GlaxoSmithKline deal

Liquidia granted GlaxoSmithKline exclusive, worldwide rights to develop certain vaccines and inhaled products using Liquidia's Particle Replication In Non-Wetting Templates (PRINT) drug delivery technology....

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >